

SUPPLEMENTARY MATERIAL

Supplemental Appendix S1. Search Terms for MEDLINE, Embase, and CENTRAL.

(A) Search for existing systematic reviews

Pubmed (Ovid)
January 1, 2019 to October 1, 2022
1. atrial fibrillation
2. coronary artery disease
3. percutaneous coronary intervention
4. 2 OR 3
5. antiplatelet
6. antithrombotic
7. anticoagul*
9. 4 OR 5 OR 6
10. meta-analysis
11. 1 AND 4 AND 9 AND 10

(B) Search for randomized controlled trials: Dual-Pathway therapy versus triple antithrombotic therapy in AF plus PCI or medically-managed ACS

Pubmed (Ovid)	Embase (Ovid)	CENTRAL (Ovid)
February 1, 2020 to October 1, 2022		
1. AF	1. AF	1. AF
2. atrial fibrillation	2. atrial fibrillation	2. atrial fibrillation
3. 1 OR 2	3. 1 OR 2	3. 1 OR 2
4. coronary stenting	4. coronary stenting	4. coronary stenting
5. coronary angioplasty	5. coronary angioplasty	5. coronary angioplasty
6. PCI	6. PCI	6. PCI
7. percutaneous coronary intervention	7. percutaneous coronary intervention	7. percutaneous coronary intervention
8. stenting	8. stenting	8. stenting
9. stent	9. stent	9. stent
10. drug-eluting stent	10. drug-eluting stent	10. drug-eluting stent
11. DES	11. DES	11. DES
12. BMS	12. BMS	12. BMS
13. bare metal stent	13. bare metal stent	13. bare metal stent
14. acute coronary syndrome	14. acute coronary syndrome	14. acute coronary syndrome
15. 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14	15. 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14	15. 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14
16. antithrombotic therapy	16. antithrombotic therapy	16. antithrombotic therapy
17. DAPT	17. DAPT	17. DAPT
18. dual antiplatelet therapy	18. dual antiplatelet therapy	18. dual antiplatelet therapy
19. clopidogrel	19. clopidogrel	19. clopidogrel
20. ticagrelor	20. ticagrelor	20. ticagrelor

21. Prasugrel 22. P2Y12 inhibitor 23. triple therapy 24. antithrombotic drugs 25. antiplatelets 26. oral anticoagulant 27. VKA 28. NOAC 29. DOAC 30. dabigatran 31. apixaban 32. edoxaban 33. rivaroxaban 34. 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33	21. Prasugrel 22. P2Y12 inhibitor 23. triple therapy 24. antithrombotic drugs 25. antiplatelets 26. oral anticoagulant 27. VKA 28. NOAC 29. DOAC 30. dabigatran 31. apixaban 32. edoxaban 33. rivaroxaban 34. 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33	21. Prasugrel 22. P2Y12 inhibitor 23. triple therapy 24. antithrombotic drugs 25. antiplatelets 26. oral anticoagulant 27. VKA 28. NOAC 29. DOAC 30. dabigatran 31. apixaban 32. edoxaban 33. rivaroxaban 34. 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33
35. 3 AND 15 AND 34 36. Limit 35 “therapy (best balance of sensitivity and specificity)”	35. 3 AND 15 AND 34 36. Limit 35 “therapy (best balance of sensitivity and specificity)”	35. 3 AND 15 AND 34

(C) Search for randomized controlled trials: OAC monotherapy versus dual-pathway therapy in AF plus CAD and remote ACS or PCI

Pubmed (Ovid) June 11, 2020 to October 1, 2022	Embase (Ovid)	CENTRAL (Ovid)
1. stable coronary 2. coronary artery disease 3. 1 OR 2	1. stable coronary 2. coronary artery disease 3. 1 OR 2	1. stable coronary 2. coronary artery disease 3. 1 OR 2
4. atrial fibrillation 5. a-fib 6. a fib 7. afib 8. 5 OR 6 OR 7	4. atrial fibrillation 5. a-fib 6. a fib 7. afib 8. 5 OR 6 OR 7	4. atrial fibrillation 5. a-fib 6. a fib 7. afib 8. 5 OR 6 OR 7
9. antithrombotic 10. oral anticoagulant 11. warfarin 12. apixaban 13. edoxaban 14. dabigatran 15. rivaroxaban 16. 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15	9. antithrombotic 10. oral anticoagulant 11. warfarin 12. apixaban 13. edoxaban 14. dabigatran 15. rivaroxaban 16. 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15	9. antithrombotic 10. oral anticoagulant 11. warfarin 12. apixaban 13. edoxaban 14. dabigatran 15. rivaroxaban 16. 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15

17. antiplatelet 18. aspirin 19. 15 OR 16	17. antiplatelet 18. aspirin 19. 15 OR 16	17. antiplatelet 18. aspirin 19. 15 OR 16
20. 3 AND 8 AND 16 AND 19 21. Limit 20 “therapy (best balance of sensitivity and specificity)”	20. 3 AND 8 AND 16 AND 19 21. Limit 20 “therapy (best balance of sensitivity and specificity)”	20. 3 AND 8 AND 16 AND 19

Supplemental Table S1. AMSTAR 2 ratings of recent relevant meta-analyses

	Khan et al 2020	Lopes 2019	Shurrab 2020	Cochrane 2019*	Gargiulo 2019	Lupercio 2020	Capodan no 2020
1. Did the research questions and inclusion criteria for the review include the components of PICO?	yes	yes	no	yes	yes	no	yes
2. Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol?	No	no	no	yes	no	no	yes
3. Did the review authors explain their selection of the study designs for inclusion in the review?	Yes	yes	yes	yes	yes	yes	yes
4. Did the review authors use a comprehensive literature search strategy?	partial yes	partial yes	partial yes	yes	no	partial yes	partial yes
5. Did the review authors perform study selection in duplicate?	yes	yes	yes	yes	yes	yes	yes
6. Did the review authors perform data extraction in duplicate?	yes	yes	yes	yes	yes	yes	yes
7. Did the review authors provide a list of excluded studies and justify the exclusions?	no	no	no	yes	yes	no	no
8. Did the review authors describe the included studies in adequate detail?	partial yes	partial yes	partial yes	yes	yes	partial yes	yes
9. Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review? (RCTs)	yes	yes	no	yes	yes	no	yes
10. Did the review authors report on the sources of funding for the studies included in the review?	yes	yes	no	yes	yes	no	no
11. If meta-analysis was performed did the review authors use appropriate methods for statistical combination of results? (RCTs)	yes	yes	yes	yes	yes	yes	yes
12. If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis?	no	yes	no	yes	yes	no	yes
13. Did the review authors account for RoB in individual studies when interpreting/ discussing the results of the review?	no	yes	no	yes	yes	no	no
14. Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review?	yes	yes	yes	yes	yes	yes	yes
15. If they performed quantitative synthesis did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review?	yes	yes	yes	yes	yes	yes	yes
16. Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review?	yes	yes	yes	yes	yes	yes	yes
Overall AMSTAR 2 rating	Critically low quality	Critically low quality	Critically low quality	High quality	Critically low quality	Critically low quality	Critically low quality

*Different focus than the present review (comparison of direct oral anticoagulants to vitamin-K antagonists, rather than a comparison of dual-pathway therapy to triple antithrombotic therapy).